Black Titan (BTTC) vs. Its Competitors Head to Head Analysis

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its rivals? We will compare Black Titan to similar businesses based on the strength of its analyst recommendations, earnings, profitability, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares Black Titan and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.61
Black Titan Competitors	$225.75 million	-$53.25 million	-10.51

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Black Titan has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, indicating that their average stock price is 32% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Black Titan and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	199	219	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 129.33%. Given Black Titan’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

57.5% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 53.7% of Black Titan shares are owned by insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.37%	-912.81%	-63.16%

Summary

Black Titan rivals beat Black Titan on 7 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.